After-Hours Movers

Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) 8.9% HIGHER; announced preclinical results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The study found that almost all of the MM cells in the model reside in a hypoxic environment in the bone marrow and that these tumor cells may be a target for tumor-specific treatment with TH-302. In vivo, animals treated prophylactically with TH-302 showed decreased serum paraprotein compared to those not treated with TH-302. The frequency of apoptotic MM cells in bone marrow sections was also significantly increased in animals treated with TH-302. In vitro, 5T33 cell-based assays demonstrated TH-302 induces cell cycle arrest and triggers apoptosis in an oxygen concentration-dependent manner. Taken together, these results support continued investigation with TH-302 as a potential treatment for multiple myeloma. Click here for the full report.

1-800-FLOWERS.COM, Inc. (NASDAQ: FLWS) 7.4% HIGHER; today reported that it has signed a definitive letter of agreement ...

Hoku Scientific, Inc. (NASDAQ: HOKU) 41% HIGHER; today announced the signing of a definitive agreement providing for a majority investment in Hoku by Tianwei and debt financing by Tianwei and China Construction Bank for the construction and development of Hoku's polysilicon production facility in Pocatello, Idaho. The transaction will involve the conversion of $50 million of an aggregate of $79 million in secured prepayments previously paid by Tianwei to Hoku under certain polysilicon supply agreements into shares of Hoku's common stock and related warrants, plus the provision of $50 million in initial debt financing for Hoku, together with a commitment from Tianwei to assist Hoku in obtaining additional financing that may be required by Hoku to construct and operate the Pocatello ...